Even after a night of sleep, individuals who have taken sleeping pills may remain too impaired to drive or execute other tasks that require alertness, according to the latest US Food and Drug Administration (FDA) safety notice about medications designed to help patients sleep.
The warning (http://tinyurl.com/b7kc4r2) focuses on the popular sleep medication zolpidem, which data reviewed by the FDA suggest may persist at levels high enough to impair driving 8 hours or more after dosing. To mitigate such risk, the FDA is recommending physicians prescribe the lowest dose necessary and is requiring manufacturers of the drugs to lower the recommended doses that appear on the drug's label. Women and individuals who have taken extended-release formulations of zolpidem may be at particularly increased risk of impaired alertness the morning after taking these medications, noted the agency.
Graphic Jump Location
Sleep medications, particularly zolpidem, may decrease a patient's alertness the next day enough to impair driving, according to the US Food and Drug Administration.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.